PubRank

Lloyd Mayer

Author PubWeight™ 134.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004 7.93
2 Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science 2013 3.74
3 Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat Med 2011 3.06
4 Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004 2.99
5 Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005 2.91
6 Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis 2012 2.23
7 Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 2008 2.16
8 The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003 2.06
9 Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur J Immunol 2008 2.05
10 The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology 2004 2.02
11 Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract. J Exp Med 2013 1.99
12 The natural history of milk allergy in an observational cohort. J Allergy Clin Immunol 2012 1.96
13 Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 2010 1.92
14 Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology 2008 1.89
15 Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003 1.70
16 The immune response in inflammatory bowel disease. Am J Gastroenterol 2007 1.67
17 A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007 1.64
18 American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007 1.60
19 Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005 1.57
20 Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 2007 1.53
21 Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood 2012 1.53
22 Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 2010 1.53
23 A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. PLoS Genet 2012 1.52
24 IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. J Biol Chem 2006 1.52
25 Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 2006 1.51
26 The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest 2010 1.50
27 Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology 2002 1.49
28 CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 2007 1.47
29 Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 2005 1.43
30 Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol 2005 1.42
31 A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 2009 1.39
32 Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism. J Immunol 2009 1.33
33 Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology 2004 1.33
34 Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes. J Allergy Clin Immunol 2009 1.30
35 Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis 2010 1.28
36 Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgamma t. Eur J Immunol 2008 1.26
37 Induction of mucosal tolerance in Peyer's patch-deficient, ligated small bowel loops. J Clin Invest 2005 1.25
38 Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy. J Allergy Clin Immunol 2010 1.25
39 Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 2013 1.24
40 Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation. Nat Commun 2011 1.23
41 Epithelial: lamina propria lymphocyte interactions promote epithelial cell differentiation. Gastroenterology 2007 1.23
42 Expression of nonclassical class I molecules by intestinal epithelial cells. Inflamm Bowel Dis 2007 1.21
43 Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal disease. Inflamm Bowel Dis 2011 1.21
44 Regulatory T cells: peace keepers in the gut. Inflamm Bowel Dis 2004 1.17
45 CD4 T cells activated in the mesenteric lymph node mediate gastrointestinal food allergy in mice. Am J Physiol Gastrointest Liver Physiol 2007 1.17
46 AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J Biol Chem 2009 1.17
47 Crohn disease: frequency and nature of CARD15 mutations in Ashkenazi and Sephardi/Oriental Jewish families. Am J Hum Genet 2004 1.17
48 Epithelia: lymphocyte interactions in the gut. Immunol Rev 2007 1.15
49 MicroRNA-7 modulates CD98 expression during intestinal epithelial cell differentiation. J Biol Chem 2009 1.12
50 Thymic stromal lymphopoietin is required for gastrointestinal allergy but not oral tolerance. Gastroenterology 2010 1.12
51 Ubiquitin-dependent degradation of interferon regulatory factor-8 mediated by Cbl down-regulates interleukin-12 expression. J Biol Chem 2005 1.11
52 Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet 2011 1.10
53 Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clin Gastroenterol Hepatol 2013 1.09
54 Activation of CD8+ regulatory T cells by human placental trophoblasts. J Immunol 2005 1.09
55 Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma. Am J Physiol Gastrointest Liver Physiol 2007 1.08
56 Gastrointestinal manifestations in primary immune disorders. Inflamm Bowel Dis 2010 1.08
57 The kinetics and pattern of tracheal allograft re-epithelialization. Am J Respir Cell Mol Biol 2003 1.07
58 Complex formation of the interferon (IFN) consensus sequence-binding protein with IRF-1 is essential for murine macrophage IFN-gamma-induced iNOS gene expression. J Biol Chem 2002 1.05
59 High levels of Crohn's disease-associated anti-microbial antibodies are present and independent of colitis in chronic granulomatous disease. Clin Immunol 2010 1.01
60 Notch-1 signaling regulates intestinal epithelial barrier function, through interaction with CD4+ T cells, in mice and humans. Gastroenterology 2010 1.00
61 Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis 2011 0.99
62 Allergic sensitization can be induced via multiple physiologic routes in an adjuvant-dependent manner. J Allergy Clin Immunol 2011 0.98
63 Orthotopic tracheal transplantation in the murine model. Transplantation 2002 0.98
64 Activation of a unique population of CD8(+) T cells by intestinal epithelial cells. Ann N Y Acad Sci 2004 0.95
65 Metabolic alterations to the mucosal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2014 0.93
66 Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2010 0.92
67 A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. Gastroenterology 2012 0.92
68 Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom 2007 0.91
69 Orthotopic tracheal allografts undergo reepithelialization with recipient-derived epithelium. Arch Otolaryngol Head Neck Surg 2003 0.90
70 A functional role for CCR6 on proallergic T cells in the gastrointestinal tract. Gastroenterology 2009 0.89
71 Mucosal epithelium in health and disease. Curr Mol Med 2005 0.88
72 Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease. Inflamm Bowel Dis 2006 0.88
73 Defect in CEACAM family member expression in Crohn's disease IECs is regulated by the transcription factor SOX9. Inflamm Bowel Dis 2009 0.87
74 Expression of the chemokine binding protein M3 promotes marked changes in the accumulation of specific leukocytes subsets within the intestine. Gastroenterology 2009 0.87
75 Oral tolerance and inflammatory bowel disease. Curr Opin Gastroenterol 2005 0.87
76 Non-classical MHC class I molecules on intestinal epithelial cells: mediators of mucosal crosstalk. Immunol Rev 2005 0.87
77 Can we produce true tolerance in patients with food allergy? J Allergy Clin Immunol 2013 0.86
78 Allergen-IgE complexes trigger CD23-dependent CCL20 release from human intestinal epithelial cells. Gastroenterology 2007 0.86
79 Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010 0.85
80 New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflamm Bowel Dis 2010 0.85
81 A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency. Gastroenterol Hepatol (N Y) 2007 0.83
82 Mucosal immunology of tolerance and allergy in the gastrointestinal tract. Immunol Res 2012 0.83
83 Immunopathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol 2002 0.82
84 Enhanced oral tolerance in transgenic mice with hepatocyte secretion of IL-10. J Immunol 2005 0.82
85 Meeting summary: Signal transduction pathways in immune and inflammatory cells. November 30-December 3, 2000, Amelia Island, Florida, U.S.A. Inflamm Bowel Dis 2003 0.81
86 Immunomodulatory roles of the carcinoembryonic antigen family of glycoproteins. Ann N Y Acad Sci 2006 0.81
87 Failure to induce oral tolerance in Crohn's and ulcerative colitis patients: possible genetic risk. Ann N Y Acad Sci 2004 0.81
88 Use of GM-CSF in the treatment of colitis associated with chronic granulomatous disease. J Allergy Clin Immunol 2005 0.81
89 Transforming growth factor β signaling controls activities of human intestinal CD8(+)T suppressor cells. Gastroenterology 2012 0.81
90 Mitochondria influence Fas expression in gp120-induced apoptosis of neuronal cells. Int J Neurosci 2009 0.80
91 The real meaning of translational research. Gastroenterology 2002 0.80
92 Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis 2009 0.79
93 Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Rev Clin Immunol 2013 0.79
94 Lymphoepithelial interactions: a new paradigm. Ann N Y Acad Sci 2009 0.78
95 Anti-inflammatory effects of the Chinese herbal formula FAHF-2 in experimental and human IBD. Inflamm Bowel Dis 2014 0.78
96 A novel approach to the treatment of ulcerative colitis: is it kosher? Gastroenterology 2005 0.77
97 Redefining autoimmunity. Gastroenterology 2003 0.77
98 Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease. Gastroenterology 2012 0.77
99 Working out mechanisms of controlled/physiologic inflammation in the GI tract. Immunol Res 2012 0.77
100 Oral tolerance: lessons on treatment of food allergy. Eur J Gastroenterol Hepatol 2005 0.76
101 Potential non-T cells source of interleukin-4 in food allergy. Pediatr Allergy Immunol 2014 0.76
102 Natural killer T cells in mucosal homeostasis. Ann N Y Acad Sci 2004 0.76
103 Hypogammaglobulinemia with facial edema. PLoS Med 2006 0.75
104 When is too much enough? Gastroenterology 2006 0.75
105 Introduction to the special issue on Immunology at Mount Sinai. Immunol Res 2012 0.75
106 A long needed re-evaluation of cells that suppress. Clin Immunol 2008 0.75
107 Treatment of disease through oral tolerance. Discov Med 2004 0.75
108 Mesalamine (5-aminosalicylic acid) therapy well tolerated in a patient with aspirin hypersensitivity and ulcerative colitis. J Clin Gastroenterol 2011 0.75
109 Living with rejection--lessons for us all. Gastroenterology 2006 0.75
110 Reepithelialization of orthotopic tracheal allografts prevents rejection after withdrawal of immunosuppression. Ann Otol Rhinol Laryngol 2005 0.75
111 Integrated Analysis of Biopsies from Inflammatory Bowel Disease Patients Identifies SAA1 as a Link Between Mucosal Microbes with TH17 and TH22 Cells. Inflamm Bowel Dis 2017 0.75